This is a news story, published by CNBC, that relates primarily to Bristol Myers Squibb news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
radiopharmaceuticals acquisitions. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest other radiopharmaceuticals news, many cancer drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
radiopharmaceuticals makersCNBC
•
76% Informative
Radiopharmaceuticals are currently available for some neuroendocrine tumors and prostate cancer.
They could one day be used for numerous cancers.
Drugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough.
Bristol Myers Squibb , AstraZeneca , Eli Lilly and other pharmaceutical companies have spent some $10 billion on deals.
Radiopharmaceuticals start decaying once they're made, so they're only good for a few days .
It could take years to understand the true potential of the technology, as many experimental drugs are still in the early phases of development.
Large pharmaceutical companies aren't waiting to jump into the race.
VR Score
84
Informative language
88
Neutral language
62
Article tone
informal
Language
English
Language complexity
57
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links